Organigram launches happly, its third hemp-derived THC brand in US

TORONTO - Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), a cannabis producer with a market capitalization of $259 million and impressive 103% stock return over the past six months according to InvestingPro, announced Thursday the introduction of happly, its third hemp-derived delta-9 THC brand in the United States, targeting consumers seeking lower-dose cannabis products.

The new brand features gummies made with the company’s proprietary FAST nanoemulsion technology, which the company claims enables more consistent onset and offset of effects. This marks the first U.S. application of this technology by Organigram.

Happly’s initial product lineup includes three varieties of gummies, each containing 2.5mg of THC and additional functional ingredients: "socialize" with caffeine, "relax" with L-theanine, and "sleep" with CBN, CBD and chamomile extract. The products come in 20-count reusable tins, with the sleep variety also available in 60-count pouches.

According to Megan McCrae, SVP of Corporate Strategy & International Growth at Organigram, the brand was developed based on consumer research indicating demand for products offering "moderation, control, predictability and specific benefits."

The company’s market research suggests the "mindful recreation" segment represents approximately 21% of cannabinoid consumers, with 63% of this group under age 34. With annual revenue of $164 million and a healthy current ratio of 2.59, Organigram appears well-positioned to expand its market presence.

Products will initially be available through direct-to-consumer sales at the brand’s website, with shipping to 23 states. Organigram plans to expand to retail channels later this year.

The launch follows Organigram’s earlier entry into the U.S. hemp-derived THC market with its Collective Project sparkling juices and Fetch sodas brands.

Organigram, which describes itself as "Canada’s #1 cannabis company by market share," operates cultivation and processing facilities in multiple Canadian locations. Trading near its 52-week high and commanding a P/E ratio of 38.9, the company shows strong momentum despite being considered overvalued according to InvestingPro Fair Value metrics. For deeper insights into Organigram’s valuation and growth potential, investors can access comprehensive analysis through InvestingPro’s detailed research reports, available for over 1,400 US-listed companies.

In other recent news, OrganiGram Holdings Inc. reported a significant 72% year-over-year increase in net revenue for Q3 2025, reaching $70.8 million. Despite this strong financial performance, the company’s stock experienced a decline in premarket trading. The earnings call highlighted OrganiGram’s focus on innovation and international expansion, with a goal of achieving a 40% gross margin by the second half of FY2026. These developments underscore the company’s strategic initiatives aimed at enhancing its market position. There were no updates on mergers or acquisitions during this period. Additionally, no analyst upgrades or downgrades were reported in relation to OrganiGram. The company’s continued emphasis on growth and expansion remains a focal point for investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.